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Education and debate
Expanding antiretroviral therapy in Malawi: drawing on
the country’s experience with tuberculosis
Anthony D Harries, Edwin Libamba, Erik J Schouten, Andrina Mwansambo, Felix M Salaniponi,
Rex Mpazanje
The DOTS (“directly observed treatment, short course”) strategy has been successfully used in
developing countries to provide effective control of tuberculosis. Field workers in Malawi are
promoting the same approach for HIV infection through the expansion of highly active
antiretroviral therapy
Highly active antiretroviral therapy (HAART) must be
expanded in sub-Saharan Africa, where the HIV/AIDS
epidemic is taking an appalling toll. Malawi, a small,
poor African country, is expanding HAART nationally.
The “directly observed treatment, short course”
(DOTS) strategy has been successfully used for years to
provide effective national control of tuberculosis, and
the same concepts are being applied for delivering
HAART. We describe how the principles of standard-
ised case finding, standardised treatment regimens,
regular monitoring and evaluation, and uninterrupted
supplies of drugs can be used to deliver HAART. If
implemented well, these principles should ensure a
controlled delivery system, which would reduce the
risks of inconsistent prescribing practices and the
development of drug resistance.
Response to Malawi’s HIV/AIDS
epidemic
In 2003 sub-Saharan Africa had an estimated 3.4 mil-
lion new cases of HIV infection and up to 2.4 million
deaths.1 Malawi has one of the highest HIV/AIDS
prevalence rates in sub-Saharan Africa, with 14% of
those aged 15-49 years infected.2 In 2003 an estimated
900 000 people had HIV/AIDS and about 86 000 died
from AIDS related illnesses. AIDS is killing young
adults in their most productive years, retarding
development, producing a huge orphan population,
and creating the foundations for political instability.
HAART has dramatically improved the survival of
patients with HIV/AIDS in developed countries,3 4
where AIDS is now regarded as a potentially treatable
and chronic condition rather than a fatal disease. In
Malawi 170 000 people are estimated to need
HAART.2 A countrywide survey by the Ministry of
Health, however, found that just over 4000 people had
started on HAART in the public and private sectors in
2003 and about 5000 were taking the medications at
the start of 2004.5 A fast track approach to expanding
treatment is urgently needed.
Fast countrywide expansion of HAART
The World Health Organization in September 2003
declared the lack of access to HAART a global health
emergency.6 The organisation called for ambitious and
unprecedented action to ensure that by the end of
2005 at least three million people needing HAART in
developing countries would have access to it—the so
called “3 by 5” initiative. Malawi has developed a two
year (2004-5) antiretroviral expansion plan, with the
goal of delivering HAART to 80 000 eligible patients
in the country by the end of 2005. The plan wants
antiretroviral drugs to be supplied free to as many eli-
gible patients as possible. It provides a detailed outline
of how antiretrovirals will be made available in a total
of 54 central, district, and mission hospitals in the
country by December 2004.
Learning from tuberculosis control
The delivery of antiretrovirals, according to standards
practised in developed countries, requires high levels
A box of the five components of the DOTS strategy and a
patient record chart for monitoring antiretroviral therapy are
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of expertise and technology. Malawi is one of the
world’s poorest countries, with a huge human
resources deficit and about $12 (£7; €10) per head of
population spent annually on health.7 The country
does not have the human or technological resources to
offer many different HAART regimens to patients or
the means to assess and monitor patients by measuring
viral load and CD4 lymphocyte counts.
Through the efforts of organisations such as WHO
and the International Union Against Tuberculosis and
Lung Disease, DOTS (similarly demanding of exper-
tise and technology in developed countries) has been
administered to millions of patients with tuberculosis
in poor countries.8 Malawi has run an effective DOTS
tuberculosis control programme for 20 years, provid-
ing diagnosis by a simple algorithm based on sputum
smear microscopy and treatment regimens recom-
mended by WHO. A rigorous system of monitoring
and evaluation enables information to be collected
nationally on case finding and treatment outcome.
Every year up to 27 000 patients access the treatment,
with acceptable success rates.9
The Malawi tuberculosis control programme is run
by paramedical staff; health assistants working as
district tuberculosis officers and clinical officers
working as regional tuberculosis officers provide
supervisory and monitoring roles (figure). The key to
success is standardisation. Every treatment facility
operates in the same way, and all regional officers con-
duct supervision using the same tools and procedures.
Tuberculosis treatment and HAART are both taken for
a long time (eight months for tuberculosis, for life for
HAART). The delivery of HAART has much to learn
from the tuberculosis services,10 and we have
developed a national plan to expand delivery of
antiretrovirals.
Framework for delivering antiretrovirals
As for DOTS, we have developed a framework for
delivering antiretrovirals that consists of a goal, specific
objectives, a strategy, a policy package, key operations,
and indicators (box 1) to measure progress with
antiretroviral therapy. National guidelines for such
treatment are available, and progress has already been
made. At the moment there are 23 antiretroviral clinics
in the public health sector delivering HAART, with the
number scheduled to increase to 54 by the end of the
year. So far, 375 healthcare workers in the public sector
have been trained to use HAART, with the number
expected to increase by an additional 100 by the end of
2004.
Eligibility criteria for treatments when
resources are limited
The commonest type of tuberculosis in Malawi is
pulmonary disease. The diagnostic algorithm stipu-
lates that all people suspected of having pulmonary
disease (defined as having a cough for three or more
weeks) have sputum smears examined for the presence
of acid-fast bacilli. Patients with acid-fast bacilli in their
sputum are registered as smear positive for pulmonary
disease, whereas those without are registered as smear
negative pulmonary disease if they fulfil certain other
criteria.11
This simple approach recognises the fact that
mycobacterial culture is not feasible in peripheral
units but that light microscopes and trained
microscopy staff are available. In a similar vein, simple
criteria have been developed for assessing eligibility
for HAART. An essential criterion is a documented
positive HIV serology test, ascertained by whole blood
rapid tests for HIV-1 and HIV-2. Adult patients known
to be HIV seropositive and who have understood the
implications of antiretroviral therapy are eligible for
HAART if they are assessed as being in clinical stages
III or IV as classified by WHO,12 in clinical stage II with
total lymphocyte count < 1200x106/l or have a CD4
count < 200x106/l. Most antiretroviral clinics will have
no access to CD4 counts and will therefore start
patients on therapy on the basis of clinical criteria.
In staff training, the diagnosis of opportunistic
infections and correct staging of disease are strongly
emphasised.
Standardised antiretroviral therapy
Malawi has stipulated its first line, alternative first line,
and second line HAART regimens (box 2). For rapid
countrywide expansion, the country has adopted the
first line regimen only, except in the few centres where
expertise already exists in using HAART regimens.
This new approach simplifies the management of
patients, the whole system of recording and reporting,
and drug procurement and drug security. It is based
on observational experience in three sites that 85-90%
of patients do well on this regimen. Patients who
develop side effects will either stop treatment or be
referred to the centres with more experienced staff
who can use alternative first line therapy. Once
antiretroviral clinics have shown they are competent
to deliver the first line regimen, they will be assessed
for their readiness to deliver alternative first line and
second line regimens according to the national
treatment guidelines.
The approach is borrowed from the tuberculosis
treatment model, where five essential first line tubercu-
Box 1: Indicators to measure progress with
delivery of antiretroviral drugs
Input indicators
A guidelines manual for delivering antiretroviral
therapy
Number of HIV clinics administering such therapy
Number of staff trained and accredited in use of
antiretroviral drugs
Antiretroviral drugs and HIV test kits always available
in hospital pharmacies, and uninterrupted supplies of
the drugs to patients
Output indicators
Number of patients who start on standardised
antiretroviral therapy
Number of patients who are still alive—and still taking
the therapy—at a given time
Percentage of patients who show 95% adherence to
the therapy
Percentage of patients having antiretroviral therapy
who have returned to work
Number of new orphans registered each year in a
district in which antiretroviral therapy is available
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losis drugs are used in slightly different combinations
to treat different forms of the disease. No investment
has been made in expensive, toxic, and difficult to
manage second line drugs for treating multidrug
resistant tuberculosis, which is rare in Malawi owing
mainly to good management with first line therapy.13
Good drug adherence and compliance with the
treatment regimen are two essential components for
successful treatment with either DOTS or HAART. In
Malawi, guardians (spouses, members of the extended
family, or sometimes children) have been used for sev-
eral years to help patients with adherence and compli-
ance with DOTS.14 15 The same principles are being
applied to HAART.While evidence is growing that this
may be a useful approach,16 not everyone is enthusias-
tic about its applicability.17
Registration, recording, and reporting
One of the important elements in preventing
multidrug resistant tuberculosis is an uninterrupted
supply of drugs. The number of cases registered
nationally for treatment in the previous two quarters
allows for realistic, six monthly procurement orders.
(The number of cases is obtained from tuberculosis
registers into which district tuberculosis officers enter
the details of every patient registered for treatment.)
The data in these registers are collated into quarterly
reports on case finding, which in turn are put together
into national reports. Standardised treatment out-
comes of patients in these quarterly cohorts are also
regularly evaluated using patient treatment cards, with
reports on cure, death, default, and transfer-out being
provided at treatment facilities and also nationally. The
system is well tried, with no drug interruptions for
years in Malawi and with regular reports on treatment
outcome.
Malawi has adopted a similar system for monitor-
ing antiretroviral therapy. Antiretroviral registers,
patient master cards and forms for quarterly cohort
analysis have already been used successfully in certain
districts. The routinely collected data should allow
regular, up to date information to be collected nation-
ally on variables such as the number of patients ever
started on HAART, the number alive, and the percent-
age of patients back in employment.
Conclusion
Expanding HAART in resource poor countries will be
a major challenge. Even if the technical difficulties of
delivering treatment can be solved, there is the
additional problem of scarcity of skilled human
resources, particularly in sub-Saharan Africa. In May
2004Malawi launched a national in-service antiretrovi-
ral training programme, and five months later it had
trained 375 medical officers, clinical officers, and
nurses in antiretroviral management at a total cost of
$85 000. With funds from WHO and the Global Fund
against AIDS, Tuberculosis and Malaria, it plans to
continue regular in-service training on HAART as well
as integrating this topic into the undergraduate
curriculum at the schools of medicine, health sciences,
and nursing. Parallel to these attempts to increase the
number of health workers able to manage HAART is
an urgent need to tackle the national crisis in human
resources, by producing more clinicians and nurses
from training institutions and to retain those entering
the service. The number of patients on HAART will
after a few years far exceed those receiving tuberculo-
sis treatment, and the human resource equation
will be vital in determining success or failure of this
intervention.
Some argue that rapid expansion in such an
environment is fraught with danger and that HAART
should rather be introduced in controlled settings
through research programmes and improved infra-
structure.18 This view ignores, however, the scale of the
problem and the urgent need to provide lifesaving
drugs to thousands of people. DOTS has a good track
record for tuberculosis control in poor areas of the
world, and if the same model for the delivery of
antiretroviral drugs can be made to work at a national
level, many lives can be saved and the risk of drug
resistance kept low.
Contributors and sources: All the authors have worked with sev-
eral other partners on producing the national antiretroviral
treatment guidelines and the national antiretroviral expansion
plan, which they are now implementing. This article is based on
the authors’ collective country based experience and is
supplemented by published, peer reviewed research on tubercu-
losis and antiretroviral therapy. Simon Makombe is an antiretro-
viral therapy officer in Malawi who has contributed considerably
to the implemenation of the expansion programme.
Box 2: Antiretroviral therapy regimens in
Malawi
First line regimen
Stavudine plus lamivudine plus nevirapine
Alternative first line regimens in cases of adverse
side effects
With severe peripheral neuropathy due to
stavudine—use zidovudine plus lamivudine plus
nevirapine
With hepatitis due to nevirapine—use stavudine plus
lamivudine plus efavirenz
Severe skin reactions due to nevirapine—use stavudine
plus lamivudine plus efavirenz
Second line regimen in the event of failure of first
line regimen
Zidovudine plus didanosine plus nelfinavir
Summary points
The DOTS (“directly observed treatment,
short course”) strategy for tuberculosis control
is of proved effectiveness in resource poor
countries
Expanding highly active antiretroviral therapy
(HAART) in countries such as Malawi may be
achieved using the same principles as for
tuberculosis control programmes
These include the adoption of standard criteria
for starting treatment and a reliable system for
registering and monitoring cases and evaluating
treatment outcomes
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Reducing maternal and neonatal mortality in the poorest
communities
Anthony Costello, David Osrin, Dharma Manandhar
Current programmes are often failing to reach those at highest risk of maternal and neonatal death.
The international community needs to learn from community trials in the South
Every year 530 000 women die from maternal causes,
four million infants die in the neonatal period, and a
similar number are stillborn.w1 w2 Despite a plethora of
newly validated interventions, the millennium develop-
ment goals to reduce maternal mortality by three
quarters and child mortality by two thirds are unlikely
to be achieved.1 One of the reasons for this is that cur-
rent safer motherhood and newborn care programmes
emphasise interventions that do not reach the poorest
households. Community based interventions have
been neglected and undervalued. In this article, we
argue that large scale community effectiveness trials
are both necessary and feasible if we are to make
further progress with reducing maternal and child
mortality.
Problems with current interventions
The fact that poor people are both more likely to
become ill and less likely to get appropriate treatment
has not changed since Tudor Hart articulated it in the
1970s.w3 This fact also underlies the fallacy of the
assumption that interventions to tackle conditions
concentrated primarily among poor people will
benefit primarily their poor victims.w4 The highest
maternal and neonatal death rates occur in poor
populations. In north India, three fifths of rural women
do not have any antenatal care;w5 in Indonesia, a third
of maternal deaths occur in the poorest quintile;w6 and
in 44 countries mothers from the richest quintile are
three times more likely to have a birth attendant than
those in the poorest quintile.
Most maternal and neonatal deaths take place at
home, beyond the reach of health facilities. Current
international policy emphasises the provision of skilled
birth attendants and improved obstetric services in
health facilities as key interventions to reduce neonatal
and maternal mortality.2 w7 The Averting Maternal
Death and Disability programme goes further in argu-
ing for a primary focus on the development of
Peer education is the best method of changing behaviour
References w1-w13 are on bmj.com
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